Protagonist Therapeutics, Inc. Shares Fell 54% Yesterday After Abandoning Phase 2 Trial Of Lead Drug
March 29, 2018 at 12:33 PM EDT
Shares of Protagonist Therapeutics dropped 54% in after-hours trading on Tuesday after announcing it would discontinue phase 2b Propel trial.